ARCA biopharma awards incentive stock options to four executives

Oruka Therapeutics, Inc.

CEO Michael Bristow received 95,000 options; COO Keuer 35,000; GC Ozeroff 27,500; CFO Dekker 17,700.
Exercise price $2.29 per share, closing price on December 14, 2021; vesting in 36 equal monthly installments.
In a change of control, 50% of unvested options accelerate; remainder vest on earlier of one year or involuntary termination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.